| 亞洲大學 |
2017-03 |
Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression
|
Hsieh, 林佑融；Yu-Jung Lin；Woei-Cherng；Woei-Cherng Shyu；Chi-Wei Chan；Chi-Wei Chang；Chi-Chung Wa；Chi-Chung Wang；Chung-Pu Wu；Chung-Pu Wu；Hsu-Tung Lee；Hsu-Tung Lee；Liang-Jwu Ch；Liang-Jwu Chen；謝佳宏；Chia-Hung |
| 國立臺灣大學 |
1999 |
Tumor Immunology - When a Cancer Cell Meets the Immune Cells
|
許世明; HSU, SU-MING |
| 臺大學術典藏 |
2018-09-10T07:47:37Z |
Tumor immunology - When a cancer cell meets the immune cells
|
Sheu, B.-C. and Hsu, S.-M. and Ho, H.-N. and Lin, R.-H. and Huang, S.-C.; BOR-CHING SHEU |
| 臺大學術典藏 |
2018-09-10T07:48:02Z |
Tumor immunology - When a cancer cell meets the immune cells
|
Sheu, B.-C. and Hsu, S.-M. and Ho, H.-N. and Lin, R.-H. and Huang, S.-C.; HONG-NERNG HO |
| 臺大學術典藏 |
2020-01-22T06:00:39Z |
Tumor immunology - When a cancer cell meets the immune cells
|
Bor-Ching Sheu;Hsu S.-M.;Ho H.-N.;Lin R.-H.;Huang S.-C.; BOR-CHING SHEU; Hsu S.-M.; Ho H.-N.; Lin R.-H.; Huang S.-C. |
| 臺大學術典藏 |
1999 |
Tumor immunology - When a cancer cell meets the immune cells
|
Huang S.-C.; Lin R.-H; HONG-NERNG HO; Hsu S.-M; Sheu B.-C; Sheu B.-C;Hsu S.-M;Hong-Nerng Ho;Lin R.-H;Huang S.-C. |
| 國立臺灣大學 |
2016 |
TUMOR INDUCED OSTEOMALACIA IN TAIWAN
|
Tsai, K. -S.; Lee, J. -C.; Shih, S. -R.; Chili, W. -Y.; Shih, S. R.; 蔡克嵩; 李仁傑; 施翔蓉 |
| 臺北醫學大學 |
1969-06 |
Tumor Inhibitions XLII Thalidasine A Novel Bisenzylisoquinoline Alkaloid Tumor Inhibitor from Thalictru dasycarpum
|
楊藏雄 |
| 臺北醫學大學 |
1969 |
Tumor Inhibitors. XLII. Thalidasine, a Novel Bisbenzylisoquinoline Alkaloid Tumor Inhibitor from Thalictrum dasycarpum
|
S. MORRIS KUPCHAN; T. H. YANG; GEORGE S. VASILIKIOTIS; MICHAEL H. BARNES; M. L. KING |
| 國家衛生研究院 |
2001-03-15 |
Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac
|
Chen, WS; Wei, SJ; Liu, JM; Hsiao, M; Lin, JK; Yang, WK |
| 國立臺灣大學 |
1988 |
Tumor Invasiveness and Prognosis in Resected Hepatocellular Carcinoma:Clinical and Pathogenetic Implications
|
許輝吉; Wu, T. T.; Wu, M. Z.; Sheu, J. C.; Lee, C. S.; Chen, D. S.; Hsieh, F. J.; Hsu, Hwei-Chi; Wu, T. T.; Wu, M. Z.; Sheu, J. C.; Lee, C. S.; Chen, D. S.; Hsieh, F. J. |
| 國立成功大學 |
2011-11 |
Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation
|
Chang, W-L |
| 臺大學術典藏 |
2021-01-26T03:36:41Z |
Tumor location on MRI determines outcomes of patients with prostate cancer after total prostate cryoablation
|
Chung-Hsin Chen;Chen Y.-C.;Pu Y.-S.; CHUNG-HSIN CHEN; Chen Y.-C.; Pu Y.-S. |
| 臺大學術典藏 |
2021-02-02T00:45:56Z |
Tumor location on MRI determines outcomes of patients with prostate cancer after total prostate cryoablation
|
Chen C.-H.;Chen Y.-C.;Yeong-Shiau Pu; Chen C.-H.; Chen Y.-C.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-03-02T14:00:17Z |
Tumor location on MRI determines outcomes of patients with prostate cancer after total prostate cryoablation
|
CHUNG-HSIN CHEN; Chen, Yu Ching; YEONG-SHIAU PU |
| 國立臺灣大學 |
2012 |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai, Wan-Ling; Liang, Po-Chin; Chen, Chien-Hung; 陳健弘; 梁博欽 |
| 臺大學術典藏 |
2018-09-10T09:15:18Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai, Wan-Ling;Liang, Po-Chin;Chen, Chien-Hung; Tsai, W.-L. and Liang, P.-C. and Chen, C.-H.; 陳健弘 ;梁博欽; Tsai, Wan-Ling; PO-CHIN LIANG; Liang, Po-Chin; Chen, Chien-Hung |
| 臺大學術典藏 |
2020-08-11T08:36:52Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; PO-CHIN LIANG; Chen C.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:20Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:28Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-06-27T07:00:18Z |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
|
Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L. |
| 國立交通大學 |
2014-12-08T15:30:29Z |
Tumor Marker Detection by Aptamer-Functionalized Graphene Oxide
|
Lin, Ming-Yu; Lu, Yen-Pei; Grumezescu, Alexandru Mihai; Ho, Fu Han; Kao, Ying-Hsien; Yang, Yuh-Shyong; Yang, Chih-Hui |
| 國立臺灣科技大學 |
2013 |
Tumor marker detection by aptamer-functionalized graphene oxide
|
Lin, M.-Y.;Lu, Y.-P.;Grumezescu, A.M.;Ho, F.H.;Kao, Y.-H.;Yang, Y.-S.;Yang, C.-H. |
| 義守大學 |
2013-01 |
Tumor Marker Detection by Aptamer-Functionalized Graphene Oxide
|
Ming-Yu Lin;Yen-Pei Lu;Alexandru Mihai Grumezescu;Fu Han Ho;Ying-Hsien Kao;Yuh-Shyong Yang;Chih-Hui Yang |
| 高雄醫學大學 |
1997 |
Tumor markers in head and neck cancer
|
郭文烈 |
